We are live on ! Find out more
AC

Aaron Cowen Suvretta Capital Management

AUM $5.47B
1-Year Est. Return 131.34%
 

Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.

This Fund
S&P 500
This Quarter Est. Return
+29.15%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$4.65B
AUM Growth
+$951M
Cap. Flow
+$238M
Cap. Flow %
5.12%
Top 10 Hldgs %
42.35%
Holding
109
New
44
Increased
20
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$233M
2
OTIS icon
Otis Worldwide
OTIS
+$135M
3
RPRX icon
Royalty Pharma
RPRX
+$107M
4
BAX icon
Baxter International
BAX
+$105M
5
FIVE icon
Five Below
FIVE
+$104M

Top Sells

Rank Stock Value
1
CRM icon
Salesforce
CRM
+$226M
2
BSX icon
Boston Scientific
BSX
+$147M
3
JNJ icon
Johnson & Johnson
JNJ
+$121M
4
FIS icon
Fidelity National Information Services
FIS
+$99.8M
5
AMZN icon
Amazon
AMZN
+$68.2M

Sector Composition

Rank Sector Weight
1 Healthcare 22.12%
2 Technology 20.81%
3 Industrials 20.34%
4 Consumer Discretionary 17.45%
5 Communication Services 11.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLQT icon
51
SelectQuote
SLQT
$146M
$13M 0.28%
+514,545
New +$13.8M
ADCT icon
52
ADC Therapeutics
ADCT
$127M
$8.2M 0.18%
+175,090
New +$6.65M
DKNG icon
53
DraftKings
DKNG
$13B
$7.05M 0.15%
+211,846
New +$5.86M
STRO icon
54
Sutro Biopharma
STRO
$349M
$7.01M 0.15%
90,280
+82,180
+1,015% +$7.89M
SLNO
55
DELISTED
Soleno Therapeutics
SLNO
$5.61M 0.12%
+168,492
New +$7.3M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.08M 0.11%
+500,000
New +$4.6M
LEGN icon
57
Legend Biotech
LEGN
$4.24B
$4.26M 0.09%
+100,000
New +$3.91M
IMVT icon
58
Immunovant
IMVT
$9.16B
$4.09M 0.09%
167,884
+131,784
+365% +$2.82M
CHRS icon
59
Coherus Oncology
CHRS
$219M
$3.24M 0.07%
181,300
+100,000
+123% +$1.69M
GSAH.U
60
DELISTED
GS Acquisition Holdings Corp II Units, each consisting of one share of Class A Common Stock and one-
GSAH.U
$3.15M 0.07%
+300,000
New +$3.15M
SURF
61
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$3.13M 0.07%
+476,879
New +$1.72M
PLRX icon
62
Pliant Therapeutics
PLRX
$71.8M
$3.07M 0.07%
+94,700
New +$2.51M
KALV
63
DELISTED
KalVista Pharmaceuticals
KALV
$2.99M 0.06%
247,000
+132,800
+116% +$1.41M
KZR
64
DELISTED
Kezar Life Sciences
KZR
$2.88M 0.06%
55,590
+46,600
+518% +$2.35M
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
$2.69M 0.06%
+268,900
New +$1.69M
CCXI
66
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$2.59M 0.06%
+45,000
New +$2.45M
ORIC icon
67
Oric Pharmaceuticals
ORIC
$1.47B
$2.58M 0.06%
+76,432
New +$2.44M
FATE icon
68
Fate Therapeutics
FATE
$279M
$2.57M 0.06%
+75,000
New +$2.24M
CLOVW
69
DELISTED
Clover Health Investments, Corp. Warrants
CLOVW
$2.53M 0.05%
+844,196
New +$2.35M
AUPH icon
70
Aurinia Pharmaceuticals
AUPH
$2.22B
$2.53M 0.05%
155,700
+74,900
+93% +$1.2M
BLU
71
DELISTED
BELLUS Health Inc.
BLU
$2.48M 0.05%
+240,900
New +$2.44M
ALBO
72
DELISTED
Albireo Pharma Inc
ALBO
$2.14M 0.05%
80,900
+31,900
+65% +$752K
EIGR
73
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.91M 0.04%
6,647
+1,320
+25% +$389K
KDNY
74
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.85M 0.04%
+160,580
New +$2.21M
ARYBU
75
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$1.74M 0.04%
+150,000
New +$1.65M
1 2
3
4 5

Similar funds

NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Aaron Cowen's Q2 2020 Portfolio in Review

As of Q2 2020, Aaron Cowen held 109 positions worth $4.65B, up 26% from $3.7B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Aaron Cowen deployed $238M of net new capital in Q2 2020, opening 44 new positions and adding to 20 existing holdings. Its largest new stake was Meta Platforms (Facebook): 1,114,740 shares worth $253M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 26% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $147M trimmed.

  • Aaron Cowen's largest Q2 2020 buy was Meta Platforms (Facebook): 1,114,740 shares worth $253M.
  • Aaron Cowen added most to Uber in Q2 2020, an estimated $82.8M increase.
  • Aaron Cowen's biggest Q2 2020 reduction was Boston Scientific, cutting an estimated $147M.
  • Aaron Cowen fully exited Salesforce in Q2 2020, selling an estimated $226M.
  • Aaron Cowen's ten largest holdings make up 42% of its $4.65B portfolio in Q2 2020.
  • Aaron Cowen opened 44 new positions and closed 29 in Q2 2020.
  • Aaron Cowen's portfolio value rose 26% quarter-over-quarter to $4.65B.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.